Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

References

• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 91:1100, 1998]. Blood. 1997;89:2079–2088. doi:10.1182/blood.V89.6.2079
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2456. doi:10.1182/blood-2012-03-420489
   PubMed Web of Science ®Google Scholar
• Leitch HA, Buckstein R, Zhu N, et al. Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21–41. doi:10.1016/j.leukres.2018.09.005
   PubMed Web of Science ®Google Scholar
• Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1–risk myelodysplastic syndromes. Ann Intern Med. 2020;172(8):513–522. doi:10.7326/M19-0916
   PubMed Web of Science ®Google Scholar
• Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010;34:1576–1588. doi:10.1016/j.leukres.2010.01.018
   PubMed Web of Science ®Google Scholar
• Musto P, Maurillo L, Simeon V, et al. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol. 2017;177:741–750. doi:10.1111/bjh.14621
   PubMed Web of Science ®Google Scholar
• Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev. 2009;23(Suppl 1):S15–19. doi:10.1016/S0268-960X(09)70005-0
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603. doi:10.1200/JCO.2005.01.7038
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Cattaneo C, Cristiani S, et al. Nontransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1:153–158. doi:10.1038/sj.thj.6200028
   PubMedGoogle Scholar
• Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6:e23109. doi:10.1371/journal.pone.0023109
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347–360. doi:10.1146/annurev-med-050109-142444
   PubMed Web of Science ®Google Scholar
• Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114:5251–5255. doi:10.1182/blood-2009-07-234062
   PubMed Web of Science ®Google Scholar
• Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005;1:191–200. doi:10.1016/j.cmet.2005.01.003
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093. doi:10.1126/science.1104742
   PubMed Web of Science ®Google Scholar
• Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142:24–38. doi:10.1016/j.cell.2010.06.028
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–1101. doi:10.1038/nm1629
   PubMed Web of Science ®Google Scholar
• Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17:184–190. doi:10.1097/MOH.0b013e328337b52f
   PubMed Web of Science ®Google Scholar
• Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94:1748–1752. doi:10.3324/haematol.2009.010322
   PubMed Web of Science ®Google Scholar
• Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics. 2010;73:527–536. doi:10.1016/j.jprot.2009.08.003
   Web of Science ®Google Scholar
• Winder A, Lefkowitz R, Ghoti H, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol. 2008;142:669–671. doi:10.1111/j.1365-2141.2008.07225.x
   PubMed Web of Science ®Google Scholar
• Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW. Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol. 2009;144:451–452. doi:10.1111/j.1365-2141.2008.07455.x
   PubMed Web of Science ®Google Scholar
• Cui R, Gale RP, Zhu G, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38:545–550. doi:10.1016/j.leukres.2014.01.016
   PubMed Web of Science ®Google Scholar
• Bondu S, Alary A-S, Lefèvre C, et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med. 2019;11:eaav5467. doi:10.1126/scitranslmed.aav5467
   Web of Science ®Google Scholar
• Zhu Y, Li X, Chang C, et al. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis. Leuk Res. 2016;44:8–16. doi:10.1016/j.leukres.2016.02.011
   Web of Science ®Google Scholar
• Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–881. doi:10.1182/blood-2014-03-563221
   PubMed Web of Science ®Google Scholar
• Vinchi F, Hell S, Platzbecker U. Controversies on the consequences of iron overload and chelation in MDS. Hemasphere. 2020;4(3):e357. doi:10.1097/HS90000000000000357
   PubMed Web of Science ®Google Scholar
• Jin S, Su H, Tran NT, et al. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PLoS One. 2017;12:e0175523. doi:10.1371/journal.pone.0175523
   Web of Science ®Google Scholar
• Dolatshad H, Pellagatti A, Fernandez-Mercado M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015;29:1092–1103. doi:10.1038/leu.2014.331
   PubMed Web of Science ®Google Scholar
• Visconte V, Avishai N, Mahfouz R, et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia. 2015;29:188–195. doi:10.1038/leu.2014.170
   Web of Science ®Google Scholar
• Inokura K, Fujiwara T, Saito K, et al. Impact of TET2 deficiency on iron metabolism in erythroblasts. Exp Hematol. 2017;49:56–67 e5. doi:10.1016/j.exphem.2017.01.002
   Web of Science ®Google Scholar
• Fabiani E, Valentini L, Cilloni D, Voso MT. Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome? - Response to Lucijanic and Kusec. Br J Haematol. 2019;186(4):639–640. doi:10.1111/bjh.15938
   Web of Science ®Google Scholar
• Della Porta MG, Kuendgen A, Malcovati L, et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood. 2008;112:11. doi:10.1182/blood-2008-02-078170
   Web of Science ®Google Scholar
• Brunner AM, Blonquist TM, Hobbs GS, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017;1:2032–2040. doi:10.1182/bloodadvances.2017010165
   PubMed Web of Science ®Google Scholar
• Pascal L, Beyne-Rauzy O, Brechignac S, et al. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol. 2013;162:413–415. doi:10.1111/bjh.12368
   PubMed Web of Science ®Google Scholar
• Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–847. doi:10.1126/science.aag1381
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–2498. doi:10.1056/NEJMoa1408617
   PubMed Web of Science ®Google Scholar
• Swirski FK. From clonal haematopoiesis to the CANTOS trial. Nat Rev Cardiol. 2018;15:79–80. doi:10.1038/nrcardio.2017.208
   Web of Science ®Google Scholar
• Vinchi F, Porto G, Simmelbauer A, et al. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J. 2019:1–16. doi:10.1093/eurheartj/ehy883
   Web of Science ®Google Scholar
• Xu S. Iron and atherosclerosis: the link revisited. Trends Mol Med. 2019;25:659–661. doi:10.1016/j.molmed.2019.05.012
   PubMed Web of Science ®Google Scholar
• Vinchi F, Muckenthaler MU, Da Silva MC, et al. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol. 2014;5:1–20.3. doi:10.3389/fphar.2014.00094
   Web of Science ®Google Scholar
• Vinchi F, Simmelbauer A, Altamura S, et al. Iron accelerates cardiovascular disease: the importance of maintaining iron balance. Atherosclerosis. 2016;252:E241–E242. doi:10.1016/j.atherosclerosis.2016.07.030
   Web of Science ®Google Scholar
• Vinchi F. Non-transferrin-bound iron in the spotlight: novel mechanistic insights into the vasculotoxic and atherosclerotic effect of iron. Antioxid Redox Signal. 2021;35(6):387–414. doi:10.1089/ars.2020.8167
   Web of Science ®Google Scholar
• Wong CAC, Leitch HA. Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. Leuk Res. 2019;83:106170. doi:10.1016/j.leukres.2019.106170
   Web of Science ®Google Scholar
• Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971–977. doi:10.1046/j.1365-2141.2000.02298.x
   PubMed Web of Science ®Google Scholar
• Milic S, Mikolasevic I, Orlic L, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144–2151. doi:10.12659/MSM.896494
   PubMed Web of Science ®Google Scholar
• Neukirchen J, Fox F, Kündgen A, et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of188 patients from the Düsseldorf MDS registry. Leuk Res. 2012;36:1067–1070. doi:10.1016/j.leukres.2012.04.006
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study. Ann Hematol. 2009;88:301–310. doi:10.1007/s00277-008-0588-3
   PubMed Web of Science ®Google Scholar
• Girmenia C, Candoni A, Delia M, et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: expert panel consensus-based recommendations. Blood Rev. 2019;34:16–25. doi:10.1016/j.blre.2018.10.002
   Web of Science ®Google Scholar
• Ganz T. Iron and infection. Int J Hematol. 2018;107:7–15. doi:10.1007/s12185-017-2366-2
   PubMed Web of Science ®Google Scholar
• Wong CAC, Wong SAY, Leitch HA. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: relation to infections and possible benefit of iron chelation therapy. Leuk Res. 2018;67:75–81. doi:10.1016/j.leukres.2018.02.005
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A, Skiada A, et al. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin. 2010;34:227–239. doi:10.3109/03630269.2010.483662
   PubMed Web of Science ®Google Scholar
• Thompson MG, Corey BW, Si Y, et al. Antibacterial activities of iron chelators against common nosocomial pathogens. Antimicrob Agents Chemother. 2012;56:5419–5421. doi:10.1128/AAC.01197-12
   PubMed Web of Science ®Google Scholar
• Neupane GP, Kim DM. In vitro time-kill activities of ciprofloxacinalone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2010;29:407–410. doi:10.1007/s10096-010-0875-5
   PubMed Web of Science ®Google Scholar
• Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res. 2017;56:88–95. doi:10.1016/j.leukres.2017.01.033
   PubMed Web of Science ®Google Scholar
• Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes. Drugs. 2011;71:155–177. doi:10.2165/11585280-000000000-00000
   Web of Science ®Google Scholar
• Angelucci E, Pilo F. Iron chelation therapy in MDS – the final answer. Clin Lymphoma Myeloma. 2019;19(S1):S75–S76. doi:10.1016/j.clml.2019.07.425
   Google Scholar
• Pilo F, Angelucci E. A storm in the niche: iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32:29–35. doi:10.1016/j.blre.2017.08.005
   Web of Science ®Google Scholar
• Porter JB, El-Alfy M, Viprakasit V, et al. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers different underlying anemias before and after deferasirox treatment. Eur J Haematol. 2016;96(1):19–26. doi:10.1111/ejh.12540
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:60–87. doi:10.6004/jnccn.2017.0007
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964. doi:10.1182/blood-2013-03-492884
   PubMed Web of Science ®Google Scholar
• Bennett JM; Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858–861. doi:10.1002/ajh.21269
   PubMed Web of Science ®Google Scholar
• Mainous AG, Tanner RJ, Hulihan MM, et al. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol. 2014;167:720–723. doi:10.1111/bjh.13053
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: that is the question! Blood Rev. 2018;32:368–377. doi:10.1016/j.blre.2018.03.002
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847–2852. doi:10.1200/JCO.2009.25.2395
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34:864–870. doi:10.1016/j.leukres.2009.12.004
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 2009;10:223–232. doi:10.1016/S1470-2045(09)70003-8
   PubMed Web of Science ®Google Scholar
• Goncalves AC, Cortesao E, Oliveiros B, et al. Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients. Clin Exp Med. 2016;16:333–343. doi:10.1007/s10238-015-0357-2
   Web of Science ®Google Scholar
• Platzbecker U, Bornhäuser M, Germing U, et al. Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS). Biol Blood Marrow Transplant. 2008;14:1217–1225. doi:10.1016/j.bbmt.2008.08.006
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing. allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95:476–484. doi:10.3324/haematol.2009.011429
   PubMed Web of Science ®Google Scholar
• Wermke M, Eckoldt J, Götze KS, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol. 2018;5:e201–e210. doi:10.1016/S2352-3026(18)30036-X
   PubMed Web of Science ®Google Scholar
• Petzer V, Wermke M, Tymoszuk P, et al. Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth. Blood Adv. 2019;3(11):1695–1700. doi:10.1182/bloodadvances.2019000043
   PubMed Web of Science ®Google Scholar
• Isidori A, Loscocco F, Visani G, et al. Iron toxicity and chelation therapy in hematopoietic stem cell transplant. Transpl Cell Ther. 2021;27:371379. doi:10.1016/j.jtct.2020.11.007
   Google Scholar
• Cremers EMP, de Witte T, de Wreede L, et al. A prospective non interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019;60:2404–2414. doi:10.1080/10428194.2019.1594215
   PubMed Web of Science ®Google Scholar
• Mahesh S, Yelena Ginzburg AV. Iron overload in myelodysplastic syndromes. Leuk Lymphoma. 2008;49:427–438. doi:10.1080/10428190701843221
   PubMed Web of Science ®Google Scholar
• Stumpf JL. Deferasirox. Am J Health Syst Pharm. 2007;64(6):606–616. doi:10.2146/ajhp060405
   Web of Science ®Google Scholar
• Vanorden HE, Hagemann TM. Deferasirox – an oral agent for chronic iron overload. Ann Pharmacother. 2006;40(6):1110–1117. doi:10.1345/aph.1G566
   Web of Science ®Google Scholar
• Shashaty G, Frankewich R, Chakraborti T, et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology. 2006;20(14):1799–1806.
   PubMed Web of Science ®Google Scholar
• Barton JC. Chelation therapy for iron overload. Curr Gastroenterol Rep. 2007;9(1):74–82. doi:10.1007/s11894-008-0024-9
   Google Scholar
• Piga A, Galanello R, Forni GL, et al. Randomized Phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880.
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597–1602. doi:10.1016/S0140-6736(03)13309-0
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462. doi:10.1182/blood-2005-08-3430
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842–848. doi:10.3324/haematol.2011.049957
   PubMed Web of Science ®Google Scholar
• Porter JB. Deferasirox: an effective once-daily orally active iron chelator. Drugs Today. 2006;42(10):623–637. doi:10.1358/dot.2006.42.10.1009901
   PubMed Web of Science ®Google Scholar
• Killick SB. Iron chelation therapy in low risk myelodysplastic syndrome. Br J Haematol. 2017;177:375–387. PMID: 28300275. doi:10.1111/bjh.14602
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Lovrinov M, Skelin M. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes. Ann Intern Med. 2020;173(7):595. doi:10.7326/L20-1055
   Web of Science ®Google Scholar
• Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179:83–97. doi:10.1111/bjh.14825
   PubMed Web of Science ®Google Scholar
• Remacha AF, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94:779–787. doi:10.1007/s00277-014-2274-y
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588–1590.
   PubMed Web of Science ®Google Scholar
• Lyons RM, Marek BJ, Paley C, et al. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2014;38:149–154. doi:10.1016/j.leukres.2013.11.004
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–1150. doi:10.1016/j.leukres.2010.03.009
   PubMed Web of Science ®Google Scholar
• Angelucci E, Santini V, Di Tucci AA, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92:527–536. doi:10.1111/ejh.12300
   PubMed Web of Science ®Google Scholar
• Nolte F, Hochsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92:191–198. doi:10.1007/s00277-012-1594-z
   PubMed Web of Science ®Google Scholar
• List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30:2134–2139. doi:10.1200/JCO.2010.34.1222
   PubMed Web of Science ®Google Scholar
• Maurillo L, Breccia M, Buccisano F, et al. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a ‘realworld’ report from two regional Italian registries: gruppo Romano Mielodisplasie and Registro Basilicata. Eur J Haematol. 2015;95:52–56. doi:10.1111/ejh.12476
   PubMed Web of Science ®Google Scholar
• Breccia M, Fisinger P, Loglisci G, et al. Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Ann Haematol. 2012;91:1345–1349. doi:10.1007/s00277-012-1481-7
   PubMed Web of Science ®Google Scholar
• Gattermann N, Jarish A, Shlag R, et al. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies Extend and EXJjange. Eur J Haematol. 2012;88(3):260–268. doi:10.1111/j.1600-0609.2011.01726.x
   PubMed Web of Science ®Google Scholar
• Rachmilewitz E, Merkel D, Ghoti H, et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood. 2008;112(11):A924–A925. doi:10.1182/blood.V112.11.2675.2675
   Web of Science ®Google Scholar
• Chan LSA, Buckstein R, Reis MD, et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood. 2008;112(11):928a. doi:10.1182/blood.V112.11.2685.2685
   Web of Science ®Google Scholar
• List AF, Baer MR, Steensma D, et al. Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood. 2008;112(11):523a.
   Web of Science ®Google Scholar
• Guzman M, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301–2307. doi:10.1182/blood.V98.8.2301
   PubMed Web of Science ®Google Scholar
• Carvalho G, Coquelle A, Vozenin MC, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107(3):1156–1165. doi:10.1182/blood-2005-05-1989
   Web of Science ®Google Scholar
• Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95(8):1308–1316. doi:10.3324/haematol.2009.016824
   PubMed Web of Science ®Google Scholar